bluebird bio Inc Hits New 52-Week Low at $21.06 (BLUE)
Shares of bluebird bio (NASDAQ:BLUE) hit a new 52-week low during trading hours on Wednesday, American Banking & Market News reports. The company traded as low as $21.06 and last traded at $22.94, with a volume of 172,751 shares trading hands. The stock had previously closed at $23.50.
Several analysts have recently commented on the stock. Analysts at Cowen and Company initiated coverage on shares of bluebird bio in a research note to investors on Tuesday, July 30th. They set an “outperform” rating and a $44.00 price target on the stock. Separately, analysts at Wedbush initiated coverage on shares of bluebird bio in a research note to investors on Monday, July 15th. They set an “outperform” rating on the stock. Finally, analysts at JPMorgan Chase & Co. initiated coverage on shares of bluebird bio in a research note to investors on Monday, July 15th. They set an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $43.67.
bluebird bio has a 52 week low of $23.03 and a 52 week high of $36.25. The stock’s 50-day moving average is $26.16 and its 200-day moving average is $28.12. The company’s market cap is $540.0 million.
bluebird bio (NASDAQ:BLUE) last released its earnings data on Thursday, August 8th. The company reported ($2.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.35) by $1.78. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $4.85 million. bluebird bio’s revenue was up 6200.0% compared to the same quarter last year. Analysts expect that bluebird bio will post $-1.39 EPS for the current fiscal year.
bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.